Janssen awarded breakthrough therapy designation for Genmab bone marrow cancer drug
The US authorities see potential for a groundbreaking treatment in talquetamab, which is being developed by Janssen based on Genmab’s technology.
by mikkel aabenhus hemmingsen, translated by catherine brett
Drug candidate talquetamab could potentially significantly improve treatment options for people with recurring or treatment-resistant bone marrow cancer, the FDA has concluded.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
